Glenmark Pharma signs licensing agreement with Torrent Pharma

11 Jul 2019 Evaluate

Glenmark Pharmaceuticals and Torrent Pharmaceuticals have entered into a non?exclusive sub?licensing agreement to co?market sodium glucose co?transporter?2 (SGLT2) inhibitor, Remogliflozin Etabonate (Remogliflozin) in India.

Under the terms of the agreement, the company will receive an upfront payment, license fees and royalties for the non?exclusive sub?license rights from Torrent. The company will manufacture and supply Remogliflozin while Torrent will market the drug under its own trademark ‘Zucator’ in India.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharma Share Price

2078.30 -34.80 (-1.65%)
08-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1761.45
Dr. Reddys Lab 1207.50
Cipla 1460.60
Zydus Lifesciences 907.60
Lupin 2190.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×